Orion CEO says Nubeqa patients are staying on treatment longer than first modeled, at Jefferies London
Orion chief executive Dr. Liisa Hurme PhD told the Jefferies Global Healthcare Conference in London that Nubeqa's safety keeps patients on treatment longer than Orion first assumed, as the drug moves into earlier prostate cancer.
